Opinion|Videos|December 4, 2024
The Clinical and Economic Impact of LEMS in SCLC Care
Author(s)Wade Iams, MD
Key Takeaways
- Disparities in healthcare access can lead to delayed diagnosis and suboptimal treatment of LEMS in small cell lung cancer patients, affecting outcomes.
- Quantifying the economic burden of LEMS requires evaluating direct medical costs, indirect costs, and patient out-of-pocket expenses.
A medical expert discusses how disparities in health care access affect the management and outcomes of Lambert-Eaton myasthenic syndrome (LEMS) in patients with small cell lung cancer, how health care providers can quantify the economic burden of LEMS on both patients and health care systems, the role of patient-reported outcomes in providing deeper insights into the clinical and economic burden of LEMS, and how health systems can utilize real-world data to better understand the indirect costs of LEMS.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do disparities in health care access affect the management and outcomes of Lambert-Eaton myasthenic syndrome (LEMS) in patients with small cell lung cancer?
- How can health care providers quantify the economic burden of LEMS on both patients and health care systems?
- In what ways can patient-reported outcomes provide deeper insights into the clinical and economic burden of LEMS?
- How can health systems utilize real-world data to better understand the indirect costs of LEMS?
Advertisement
Related to this article
The new NCCN Guidelines for Patients: Caregiving for People With Cancer address finances, legal concerns, and household tasks alongside medical management, areas that an expert involved in their development says “often leave people reeling.”
The FDA approved talazoparib plus enzalutamide for HRR-mutated metastatic hormone-sensitive prostate cancer after TALAPRO-3 cut progression risk by 52%.
Unclear ownership often leaves survivors without support, and coverage of social and psychological services could close the gap, says Bhatnagar.
Adults with moderately to severely active Crohn disease can now start risankizumab with an on-body injector at home.
This system-level initiative significantly increased guideline-concordant venous thromboembolism prophylaxis rates in hospitalized patients through coordinated education, clinical decision tools, audit-feedback, and pharmacist integration.
For all the advances in breast cancer, there remains unmet need for patients whose cancer progresses after treatment with antibody-drug conjugates (ADCs). In the final week of Breast Cancer Awareness Month, AJMC® looks at an investigational vaccine approach that could come after ADCs, offering patients a low-toxicity regimen.
Nevena Vicic, MSc, discusses first real-world data showing mRNA-1283 protected adults 65 and older from COVID-19 hospitalization in 2025-2026.
He sees progress in Richter combination therapies, explains how patient goals shape CLL treatment, and reflects on mentoring trainees.
Advertisement
Advertisement
Trending on AJMC
1
Preparing for Hepatitis B Functional Cure: Jordan Feld, MD, MPH
2
IDWeek Studies Tie RSV, Flu, and COVID-19 to Harm After Acute Illness
3
Povetacicept Cuts Proteinuria by 52% in IgA Nephropathy at Week 36
4
FDA Approves Talazoparib Plus Enzalutamide for HRR-Mutated mHSPC
5